Answers are grounded in this paper and cite their sources.
This analysis identifies biomarker diversity in patients receiving lecanemab, indicating important clinical implications.
We identified substantial heterogeneity in ATNIVS biomarker profiles among patients receiving lecanemab in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Kurihara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: